Trials / Not Yet Recruiting
Not Yet RecruitingNCT07212322
A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases
A Study to Evaluate the Safety and Efficacy of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and efficacy of CD19 UCAR-T cell therapy in Subjects with autoimmune diseases.
Detailed description
This is a single-center, one-arm, open-label study aiming to evaluate the safety and efficacy of CD19 UCAR-T Cellsin subjects with autoimmune diseases. The study process is divided into five periods, including screening, lymphodepletion, treatment, DLT observation and follow-up.
Conditions
- Systemic Lupus Erythematosus
- Idiopahic Inflammatory Myopathies
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Sjögren's Syndrome
- Antiphospholipid Syndrome
- Immune Thrombocytopenia
- Systemic Sclerosis
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CD19 UCAR-T cells | CD19 UCAR-T cells treatment |
Timeline
- Start date
- 2026-01-30
- Primary completion
- 2027-05-20
- Completion
- 2027-07-20
- First posted
- 2025-10-08
- Last updated
- 2025-12-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07212322. Inclusion in this directory is not an endorsement.